Polaryx Therapeutics appointed Will Charlton as chief medical officer effective September 1, 2026. The role matters to investors because Charlton is expected to lead clinical execution ahead of the company’s planned SOTERIA trial initiation in the fourth quarter of 2026, including development of PLX-200 for rare pediatric disorders.

Key Highlights

  • Will Charlton brings experience in pediatric endocrinology, rare disease and clinical development.
  • Charlton previously held senior roles at Tyra Biosciences, Spruce Biosciences and 89bio.
  • Charlton is Polaryx Therapeutics, Inc.’s chief medical officer.

The appointment comes ahead of Polaryx Therapeutics, Inc. (NASDAQ: PLYX)’s planned SOTERIA trial initiation in the fourth quarter of 2026, with Charlton set to lead clinical execution and advance key milestones.

Charlton Takes Charge of Rare-Disease Development

He spent over a decade in clinical practice and has held senior clinical development and chief medical officer positions across biotechnology companies. At Tyra Biosciences, Charlton served as senior vice president of clinical development for skeletal dysplasia between 2025 and 2026. Earlier, at 89bio between 2020 and 2022, he led clinical development for pegozafermin in MASH and severe hypertriglyceridemia. For the CLN2 and CLN3 cohorts, natural-history data will be used for comparisons with treated patients.